SOCIOECONOMIC BURDEN OF HER2-POSITIVE BREAST CANCER IN ALGERIA: A PREVALENCE-BASED COST-OF-ILLNESS ANALYSIS
Author(s)
Hamida Zaidi, PharmD1, Radia Bensemmane, Prof2, Yasmine Amroun, BSc3, Islam. Anan, PharmD4, Malina Müller, BA, MA, PhD5, Khalifa Islam BENGANA, PharmD3.
1University of health sciences, Algiers, Algeria, 2Ministry of Health, Algeria, Algiers, Algeria, 3Roche Algérie SPA, Algiers, Algeria, 4Accsight, Cairo, Egypt, 5WifOR Institute, Darmstadt, Germany.
1University of health sciences, Algiers, Algeria, 2Ministry of Health, Algeria, Algiers, Algeria, 3Roche Algérie SPA, Algiers, Algeria, 4Accsight, Cairo, Egypt, 5WifOR Institute, Darmstadt, Germany.
OBJECTIVES: To quantify the direct and indirect annual economic burden of HER2-positive (HER2+) breast cancer (BC) among treated patients in Algeria.
METHODS: A prevalence-based cost-of-illness model was developed using patient-level data from an oncology institution in Algeria. Epidemiological inputs drew from GLOBOCAN 5-year prevalence estimates and expert-validated stage and subtype distributions. Resource use across diagnosis, monitoring, surgery, chemotherapy, targeted therapy, radiotherapy, and hospitalization was valued at nationally applicable unit costs. Indirect costs from patient and caregiver work absenteeism.
RESULTS: An estimated 23,066 Algerians carry HER2+ BC, of whom approximately 18,453 receive treatment annually; Stage II (45.2%) and Stage III (33.6%) predominate, with Stage I and IV representing 7.1% and 14.2%. The total annual economic burden reaches DZD 18.4 billion (USD 137.7 million), with a mean cost per treated patient of DZD 997,435 (USD 7,462). Targeted therapy is the dominant cost driver, representing 54.1% of total expenditure (DZD 9.95 billion; USD 74.5 million). Radiotherapy is the second largest contributor at 32.5% (DZD 5.98 billion; USD 44.7 million), concentrated in Stages II-III. Chemotherapy accounts for 4.1%, diagnostic workup for 3.7%, and disease monitoring for 1.9%. Indirect costs from patient and caregiver work absenteeism represent 2.3% of the total burden (DZD 424.8 million; USD 3.2 million). Per-patient costs peak in Stage IV, driven by intensive targeted therapy combinations.
CONCLUSIONS: HER2+ BC imposes a substantial economic burden on Algeria's healthcare system. Targeted therapy is the dominant cost driver, underscoring the need for optimized treatment sequencing and value-based reimbursement frameworks to ensure sustainable patient access.
METHODS: A prevalence-based cost-of-illness model was developed using patient-level data from an oncology institution in Algeria. Epidemiological inputs drew from GLOBOCAN 5-year prevalence estimates and expert-validated stage and subtype distributions. Resource use across diagnosis, monitoring, surgery, chemotherapy, targeted therapy, radiotherapy, and hospitalization was valued at nationally applicable unit costs. Indirect costs from patient and caregiver work absenteeism.
RESULTS: An estimated 23,066 Algerians carry HER2+ BC, of whom approximately 18,453 receive treatment annually; Stage II (45.2%) and Stage III (33.6%) predominate, with Stage I and IV representing 7.1% and 14.2%. The total annual economic burden reaches DZD 18.4 billion (USD 137.7 million), with a mean cost per treated patient of DZD 997,435 (USD 7,462). Targeted therapy is the dominant cost driver, representing 54.1% of total expenditure (DZD 9.95 billion; USD 74.5 million). Radiotherapy is the second largest contributor at 32.5% (DZD 5.98 billion; USD 44.7 million), concentrated in Stages II-III. Chemotherapy accounts for 4.1%, diagnostic workup for 3.7%, and disease monitoring for 1.9%. Indirect costs from patient and caregiver work absenteeism represent 2.3% of the total burden (DZD 424.8 million; USD 3.2 million). Per-patient costs peak in Stage IV, driven by intensive targeted therapy combinations.
CONCLUSIONS: HER2+ BC imposes a substantial economic burden on Algeria's healthcare system. Targeted therapy is the dominant cost driver, underscoring the need for optimized treatment sequencing and value-based reimbursement frameworks to ensure sustainable patient access.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE242
Topic
Economic Evaluation, Health Technology Assessment, Methodological & Statistical Research
Topic Subcategory
Novel & Social Elements of Value, Work & Home Productivity - Indirect Costs
Disease
Oncology